1 |
Liu, X. W., Tang, C. L., Zheng, H., Wu, J. X., Wu, F., Mo, Y. Y., Liu, X., Zhu, H. J., Yin, C. L., Cheng, B., Ruan, J. X., Song, F. M., Chen, Z. N., Song, H., Guo, H. W., Liang, Y. H. and Su, Z. H. 2018. Investigation of the hepatoprotective effect of Corydalis saxicola Bunting on carbon tetrachloride-induced liver fibrosis in rats by H-NMR-based metabonomics and network pharmacology approaches. J. Pharm. Biomed. Anal. 159, 252-261.
DOI
|
2 |
Raeeszadeh-Sarmazdeh, M., Do, L. D. and Hritz, B. G. 2020. Metalloproteinases and their inhibitors: Potential for the development of new therapeutics. Cells 9, 1313.
DOI
|
3 |
Tombulturk, F. K., Soydas, T., Sarac, E. Y., Tuncdemir, M., Coskunpinar, E., Polat, E., Sirekbasan, S. and Kanigur-Sultuybek, G. 2019. Regulation of MMP 2 and MMP 9 expressions modulated by AP-1 (c-jun) in wound healing: improving role of Lucilia sericata in diabetic rats. Acta Diabetol. 56, 177-186.
DOI
|
4 |
Malemud, C. 2006. Matrix metalloproteinases (MMPs) in health and disease: an overview. Front. Biosci. 11, 1696-1701.
DOI
|
5 |
Morales-Vasquez, F., Castillo-Sanchez, R., Gomora, M. J., Almaraz, M. A., Pedernera, E., Perez-Montiel, D., Rendon, E., Lopez-Basave, H. N., Roman-Basaure, E., Cuevas-Covarrubias, S., Maldonado-Cubas, J., Villa, A. and Mendez, C. 2020. Expression of metalloproteinases MMP-2 and MMP-9 is associated to the presence of androgen receptor in epithelial ovarian tumors. J. Ovarian Res. 13, 86.
DOI
|
6 |
Murphy, G. 2011. Tissue inhibitors of metalloproteinases. Genome Biol. 12, 233.
DOI
|
7 |
Bae, M. J., Karadeniz, F., Oh, J. H., Yu, G. H., Jang, M. S., Nam, K. H., Seo, Y. and Kong, C. S. 2017. MMP-inhibitory effects of flavonoid glycosides from edible medicinal halophyte Limonium tetragonum. Evid. Based Complement. Alternat. Med. 2017, 6750274.
|
8 |
Barabas, L., Hritz, I., Istvan, G., Tulassay, Z. and Herszenyi, L. 2021. The behavior of MMP-2, MMP-7, MMP-9, and their inhibitors TIMP-1 and TIMP-2 in adenoma-colorectal cancer sequence. Dig. Dis. 39, 217-224.
DOI
|
9 |
Gonzalez-Avila, G., Sommer, B., Mendoza-Posada, D. A., Ramos, C., Garcia-Hernandez, A. A. and Falfan-Valencia, R. 2019. Matrix metalloproteinases participation in the metastatic process and their diagnostic and therapeutic applications in cancer. Crit. Rev. Oncol. Hematol. 137, 57-83.
DOI
|
10 |
Kajanne, R., Miettinen, P., Mehlem, A., Leivonen, S. K., Birrer, M., Foschi, M., Kahari, V. M. and Leppa, S. 2007. EGF-R regulates MMP function in fibroblasts through MAPK and AP-1 pathways. J. Cell. Physiol. 212, 489-497.
DOI
|
11 |
Kumar, G. B., Nair, B. G., Perry, J. J. P. and Martin, D. B. C. 2019. Recent insights into natural product inhibitors of matrix metalloproteinases. Medchemcomm 10, 2024-2037.
DOI
|
12 |
Lv, Y., Zhao, X., Zhu, L., Li, S., Xiao, Q., He, W. and Yin, L. 2018. Targeting intracellular MMPs efficiently inhibits tumor metastasis and angiogenesis. Theranostics 8, 2830-2845.
DOI
|
13 |
Wu, Z., He, D., Zhao, S. and Wang, H. 2019. IL-17A/IL-17RA promotes invasion and activates MMP-2 and MMP-9 expression via p38 MAPK signaling pathway in non-small cell lung cancer. Mol. Cell. Biochem. 455, 195-206.
DOI
|
14 |
Safranek, J., Pesta, M., Holubec, L., Kulda, V., Dreslerova, J., Vrzalova, J., Topolcan, O., Pesek, M., Finek, J. and Treska, V. 2009. Expression of MMP-7, MMP-9, TIMP-1 and TIMP-2 mRNA in lung tissue of patients with non-small cell lung cancer (NSCLC) and benign pulmonary disease. Anticancer Res. 29, 2513-2517.
|